CRISPR/Cas9 is a targeted genome editing tool, first discovered in bacteria, containing two components – a guide RNA (gRNA) and a Cas9 nuclease. This versatile system enables researchers to produce targeted gene modifications, including gene knockouts, large integrations, point mutations, and gene tagging in cell lines, animal models, plants, and bacteria. CRISPR/Cas9 can also function in a nuclease-independent manner that inhibits (CRISPRi) or activates (CRISPRa) gene expression for further genetic pathway interrogation.
The low cost and ease-of-use of CRISPR mean it is now easier than ever to utilize in individual experiments or at whole-genome scale for screening applications.
CompoZr® Zinc Finger Nucleases (ZFNs) are a class of engineered DNA-binding proteins that facilitate targeted editing of the genome by creating double-strand breaks using the Fok1 endonuclease. ZFNs have high on-target specificity, making them excellent tools for pre-clinical and clinical therapeutic development. For large targeted integrations, ZFNs often display higher efficiency than other gene editing tools.
With decades of gene editing experience and numerous global patents for CRISPR technology, the Sigma-Aldrich® portfolio provides high quality reagents for your entire workflow, so you can edit with confidence. Take your research Beyond the Bench with the comprehensive Sigma-Aldrich® suite of CRISPR and ZFN gene-editing tools and services.